TABLE 2.
Pharmacological effects and mechanisms of action of extract from Phyllanthus emblica.
No. | Dose | Pharmacology activity | Mechanism | References |
---|---|---|---|---|
1 | 50 and 100 μg/mL | Antioxidant | - enhancing reducing power and total antioxidant capacity, scavenging hydroxil radical and superoxide anion | Uddin et al. (2016); Li et al. (2020) |
- Reduced peroxidation level | ||||
- Induced defense system (GSH, SOD, CAT, GPx, GSH reductase, and GSH S-transferase) | ||||
2 | 50 and 100 μg/mL | Antiinflammatory | - Inhibited Nitric Oxide (NO) and COX-2 (dose-dependent) | Li et al. (2022) |
3 | 100; 200; 500 mg/kg BW | Immunomodulatory | - Induced the activity of GSH, CAT, and SOD in the thymus of mice | Ghosh et al. (2013); Saini et al. (2022) |
- increased the hemagglutination antibody titer, leukocytes count, the percentage of lymphocytes distribution, and delayed hypersensitivity in mice | ||||
4 | 500 mg/kg BW | Hepatoprotective | - Gallic acid content improves high fat diet induced dyslipidemia, hepatosteatosis, and oxidative stress | Huang et al. (2017) |
- increasing adiponectin in adipocytes and PPAR-α in the liver and decreasing SREBP-1c in the liver | ||||
5 | Dose dependent | Neuroprotective | - Conferred PC12 cells protection against H2O2-induced cell death | Li et al. (2022) |
6 | 50 and 100 mg/kg BW | Cardioprotective | - The emblicanin A and B contents reversed the effects of IRI (ischaemia reperfusion injury) | Priya and Islam (2019) |
7 | 25 and 50 μg/mL | Anticancer | - Phenolic acid and flavonoid content inhibited cell migration | Samatiwat et al. (2021) |
8 | 2 mL/kg/day | Antihyperlipidemic | - Activated PPARα and carnitine palmitoyl transferase (involved in lipid oxidation) | Variya et al. (2016) |
- Reduced the serum triglycerides | ||||
9 | 500 mg/TDS | Antihypertensive | - Reduced systolic and diastolic blood pressure | Ghaffari et al. (2020) |
10 | 50 and 25 mg/mL | Antimicrobial | - Methanolic extract showed potent antimicrobial activity to antimicrobial-resistant (AMR) Salmonella Typhi and Salmonella Enteritidis; Bacillus subtilis, Staphylococcus aureus and Shigella dysenteriae; Pseudomonas aeruginosa | Nair et al. (2020); Jahan and Akter (2015); Farhana et al. (2022) |
11 | 250 and 500 mg/kg BW | Anti-diarrheal | - Inhibited the biosynthesis of prostaglandin through antisecretory mechanism | Afrin et al. (2016) |
12 | 1.2 mg/mL | Anti-aging | - Reduced the activity of AchE, BuChE; enhanced antioxidant enzymes activity of SOD and CAT; decrease MDA level | Wu et al. (2022b) |
13 | 100 and 300 mg/kg BW | Laxative | - The crude extract increased the production of wet feces at a mechanism similar to the effect of standard drug carbachol | Mehmood et al. (2013) |